An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus

References

• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128. .
   PubMed Web of Science ®Google Scholar
• Libby P, Loscalzo J, Ridker PM, et al. Inflammation, Immunity, and Infection in Atherothrombosis. J Am Coll Cardiol. 2018;72:2071–2081. https://linkinghub.elsevier.com/retrieve/pii/S0735109718369572.
   PubMed Web of Science ®Google Scholar
• Robbins SL, Kumar V, Abbas AK, JCA. Robbins & Cotran pathologic basis of disease. 9th ed. Elsevier; 2015.
   Google Scholar
• Ohman EM, Bhatt DL, Steg PG, et al. The Reduction of Atherothrombosis for Continued Health (REACH) registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151(4):786.e1-786.e10.
   Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Wilson PWF, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–1206. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17374814.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Bhatt DL, Eikelboom JW, et al. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol [Internet]. 2020;17:242–257. Available from: http://www.nature.com/articles/s41569-019-0314-y.
   PubMed Web of Science ®Google Scholar
• Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421.
   PubMed Web of Science ®Google Scholar
• Stratton IM. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412.
   PubMed Web of Science ®Google Scholar
• Beckman JA, Paneni F, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J. 2013;34:2444–2452.
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation [Internet]. 2011 cited 2018 Feb 13;123:798–813. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/CIRCULATIONAHA.109.913376.
   PubMed Web of Science ®Google Scholar
• Park Y, Franchi F, Rollini F, et al. Antithrombotic therapy for secondary prevention in patients with diabetes mellitus and coronary artery disease. Circ J. 2016;80:791–801.
   PubMed Web of Science ®Google Scholar
• Bellemain-Appaix A, Brieger D, Beygui F, et al. New P2Y12Inhibitors versus clopidogrel in percutaneous coronary intervention. J Am Coll Cardiol. 2010;56:1542–1551.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39:119–177.
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J [Internet]. 2016;37:267–315. Available from: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehv320.
   PubMed Web of Science ®Google Scholar
• Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention. 2019 Feb 20;14(14):1435-1534. doi: 10.4244/EIJY19M01_01.
   Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–2381.
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation [Internet]. 2019;CIR0000000000000678. [cited 2020 July 9]. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.040625.
   Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73:e285–e350.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71:e127–e248.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med [Internet]. 2016;375:311–322. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27295427.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Ingala S, Calderone D, et al. Aspirin for the primary prevention of cardiovascular disease: latest evidence. Expert Rev Cardiovasc Ther. 2019 Sep;17(9):633-643. doi: 10.1080/14779072.2019.1651199. Epub 2019 Aug 16.
   Web of Science ®Google Scholar
• Zhang Y, Zhang S, Ding Z. Role of P2Y12 receptor in thrombosis. Germany: Springer; 2016. p. 307–324.
   Google Scholar
• Angiolillo DJ, Bernardo E, Capodanno D, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol. 2010;55:1139–1146.
   PubMed Web of Science ®Google Scholar
• Meves SH, Schröder KD, Endres HG, et al. Clopidogrel High-on-Treatment Platelet Reactivity in Acute Ischemic Stroke Patients. Thromb Res. 2014;133:396–401.
   PubMed Web of Science ®Google Scholar
• Teng R. Ticagrelor: pharmacokinetic, pharmacodynamic and pharmacogenetic profile: an update. Clin Pharmacokinet. 2015;54:1125–1138.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Dharmashankar K, Angiolillo DJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther [Internet]. 2010;8:151–158. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20136601.
   PubMedGoogle Scholar
• Rollini F, Franchi F, Cho JR, et al. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur Heart J [Internet]. 2016;37:2722–2730. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26848148.
   PubMed Web of Science ®Google Scholar
• Akers WS, Oh JJ, Oestreich JH, et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 Receptor antagonist. J Clin Pharmacol. 2010;50:27–35.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012;34:44–55.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Milluzzo RP, Angiolillo DJ. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use. Ther Adv Cardiovasc Dis. 2019;13:175394471989327.
   Google Scholar
• Milluzzo RP, Franchina GA, Capodanno D, et al. Selatogrel, a novel P2Y 12 inhibitor: a review of the pharmacology and clinical development. Expert Opin Investig Drugs. 2020; May 12;1-10. doi: 10.1080/13543784.2020.1764533.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes. Drugs [Internet]. 2012 cited 2018 Apr 22;72:2087–2116. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23083110.
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y 12 antagonists. Semin Thromb Hemost. 2005;31:195–204.
   PubMed Web of Science ®Google Scholar
• Springthorpe B, Bailey A, Barton P, et al. From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett. 2007;17:6013–6018.
   PubMed Web of Science ®Google Scholar
• Kim S, Chen J, Cheng T, et al. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2019;47:D1102–D1109.
   PubMed Web of Science ®Google Scholar
• Husted S, van Giezen JJJ. Ticagrelor: the First reversibly binding oral P2Y 12 receptor antagonist. Cardiovasc Ther. 2009;27:259–274.
   PubMed Web of Science ®Google Scholar
• JJJ VANGIEZEN, NILSSON L, BERNTSSON P, et al. Ticagrelor binds to human P2Y 12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7:1556–1565.
   PubMed Web of Science ®Google Scholar
• van Giezen JJJ. Optimizing platelet inhibition. Eur Heart J. 2008;29:1925–1926.
   Web of Science ®Google Scholar
• EMA. Ticagrelor assessment report. 2011.
   Google Scholar
• FDA. Ticagrelor full prescribing information. 2015.
   Google Scholar
• Teng R, Oliver S, Hayes MA, et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38:1514–1521.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor. J Am Coll Cardiol [Internet]. 2014 cited 2018 Jan 1;63:2503–2509. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24768873.
   PubMed Web of Science ®Google Scholar
• Wang K, Zhou X, Zhou Z, et al. Blockade of the platelet P2Y 12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol. 2003;23:357–362.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Faioni EM. Why does ticagrelor induce dyspnea? Thromb Haemost [Internet]. 2012;108:1031–1036. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23070079.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Cannon CP, Emanuelsson H, et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:1908–1916.
   PubMed Web of Science ®Google Scholar
• Storey RF, James SK, Siegbahn A, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets [Internet]. 2014 cited 2018 Jan 1;25:517–525. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24127651.
   PubMed Web of Science ®Google Scholar
• Sexton TR, Zhang G, Macaulay TE, et al. Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. JACC Basic to Transl Sci. 2018;3:435–449.
   PubMedGoogle Scholar
• Lancellotti P, Musumeci L, Jacques N, et al. Antibacterial activity of ticagrelor in conventional antiplatelet dosages against antibiotic-resistant gram-positive bacteria. JAMA Cardiol. 2019;4:596.
   PubMed Web of Science ®Google Scholar
• Wright JR, Chauhan M, Shah C, et al. The TICONC (Ticagrelor-Oncology) study. JACC Cardio Oncol. 2020;2:236–250.
   PubMedGoogle Scholar
• van Vuren AJ, de Jong B, Bootsma HPR, et al. Ticagrelor-induced renal failure leading to statin-induced rhabdomyolysis. Neth J Med. 2015;73:136–138.
   PubMed Web of Science ®Google Scholar
• Kido K, Wheeler MB, Seratnahaei A, et al. Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin. J Am Pharm Assoc. 2015;55:320–323.
   Google Scholar
• Sugidachi A, Asai F, Ogawa T, et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129:1439–1446.
   PubMed Web of Science ®Google Scholar
• Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37:245–252.
   PubMed Web of Science ®Google Scholar
• Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-Elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2014 Dec 31;8(1):e001593.
   Google Scholar
• Franchi F, Rollini F, Park Y, et al. Effects of methylnaltrexone on ticagrelor-induced antiplatelet effects in coronary artery disease patients treated with morphine. JACC Cardiovasc Interv [Internet]. 2019;12:1538–1549. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31377269.
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Trenk D, Krähenbühl S, et al. Clinical implications of drug-drug interactions with P2Y 12 receptor inhibitors. J Thromb Haemost. 2014;12:2–13.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med [Internet]. 2009;361:1045–1057. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0904327. .
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation [Internet]. 2011 cited 2018 Jan 1;124:544–554. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/CIRCULATIONAHA.111.047498.
   PubMed Web of Science ®Google Scholar
• Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010;66:487–496.
   PubMed Web of Science ®Google Scholar
• Peters G. RG. Single-dose pharmacokinetics and pharmacodynamics of AZD6140 – an oral reversible ADP receptor antagonist. Haematologica. 2004;989(Suppl.):14–15.
   Google Scholar
• Peters GR, Butler KAWH. Multiple-dose pharmacokinetics (PK) and pharmacodynamics (PD) of the oral reversible, orally active ADP receptor antagonist AZD6140. Eur Heart J. 2006;27(Suppl 1):4556.
   Google Scholar
• Butler K, Winter H, Mitchell P, et al. Pharmacokinetics and pharmacodynamics of AZD6140, the first reversible oral P2Y12 receptor antagonist, administered with aspirin [abstract 92]. J Clin Pharmacol. 2007;47–1204.
   Google Scholar
• Butler KTR. AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, exhibits linear pharmacokinetics following multiple doses in healthy subjects, with greater and less variable inhibition of platelet aggregation compared with clopidogrel [abstract 562. Can J Clin Phamracol. 2008;15:e684–e685.
   Google Scholar
• Teng RBK. AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, has linear pharmacokinetics and provides near complete inhibition of platelet aggregation, with reversibility of effect, in healthy subjects [abstract 9. Can J Clin Pharmacol. 2008;15:e426.
   Google Scholar
• Rosenstein R. Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor. J Blood Med. 2010; 2010;1:197-219.
   PubMedGoogle Scholar
• Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038–1047.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non–ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2007;50:1844–1851.
   PubMed Web of Science ®Google Scholar
• Husted S, Harrington RA, Cannon CP, et al. Bleeding risk with AZD6140, a reversible P2Y 12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. Int J Clin Pract. 2009;63:667–670.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation [Internet]. 2010 cited 2017 Aug 17;121:1188–1199. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/CIRCULATIONAHA.109.919456.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for Coronary Stenting. Circulation. 2003;107:2908–2913.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005;45:1392–1396.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y 12 receptor–inhibiting therapies. Circulation [Internet]. 2017 cited 2018 Mar 31;136:1955–1975. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29084738.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Rivas Rios J, et al. Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease: results of the SWAP-4 study. Circulation [Internet]. 2018;137:2450–2462. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29526833.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–2585.
   PubMed Web of Science ®Google Scholar
• Dobesh PP, Patel M. The PARTHENON clinical development program: the role of ticagrelor in patients with atherothrombotic disease. Cardiovasc Drugs Ther. 2017;31:433–444.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800. .
   PubMed Web of Science ®Google Scholar
• Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med [Internet]. 2016 cited 2017 Dec 17;375:35–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27160892.
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Fowkes FGR, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. 2017 cited 2017 Dec 17;376:32–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27959717.
   Google Scholar
• Johnston SC, Amarenco P, Denison H, et al. The acute Stroke or Transient Isc h emic Attack Treated with Tic a gre l or and Aspirin for Prevention of Stroke and Death (THALES) trial: rationale and design. Int J Stroke. 2019;14:745–751.
   PubMed Web of Science ®Google Scholar
• James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J [Internet]. 2010;31:3006–3016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20802246.
   PubMed Web of Science ®Google Scholar
• Franchi F, James SK, Ghukasyan Lakic T, et al. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. J Am Heart Assoc [Internet]. 2019;8:e011139. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30857464.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS–TIMI 54. J Am Coll Cardiol. 2016;67:2732–2740.
   PubMed Web of Science ®Google Scholar
• Astra Zeneca. BRILINTA (ticagrelor) prescribing information. 2016.
   Google Scholar
• Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381:1309–1320. .
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox K, Harrington RA, et al. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clin Cardiol. 2019;42:498–505.
   PubMed Web of Science ®Google Scholar
• Storey RF, Angiolillo DJ, Bonaca MP, et al. Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol. 2016;67:1145–1154.
   PubMed Web of Science ®Google Scholar
• Thomas MR, Angiolillo DJ, Bonaca MP, et al. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thromb Haemost. 2017;117:940–947.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394:1169–1180. .
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL. Is there really a benefit to net clinical benefit in testing antithrombotics? Circulation [Internet]. 2018;137:1429–1431. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29610124.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Kalidindi S, et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol [Internet]. 2008;52:255–262. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18634979.
   PubMed Web of Science ®Google Scholar
• Nakanishi R, Ceponiene I, Osawa K, et al. Plaque progression assessed by a novel semi-automated quantitative plaque software on coronary computed tomography angiography between diabetes and non-diabetes patients: A propensity-score matching study. Atherosclerosis [Internet]. 2016;255:73–79. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27835741.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Been L, et al. Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen versus Standard Dose Clopidogrel in Diabetes Mellitus Patients without Prior Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-6 study. Circulation. Circulation. 2020. DOI: 10.1161/CIRCULATIONAHA.120.048770.
   PubMed Web of Science ®Google Scholar
• Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N. Engl. J. Med. 2020;383:207–217.
   Google Scholar
• Goto S, Huang C-H, Park S-J, et al. Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese Patients With Acute Coronary Syndrome – randomized, Double-Blind, Phase III PHILO Study –. Circ J. 2015;79:2452–2460.
   PubMed Web of Science ®Google Scholar
• Park D-W, Kwon O, Jang J-S, et al. Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial. Circulation [Internet]. 2019;140:1865–1877. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31553203.
   PubMed Web of Science ®Google Scholar
• Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary interventionclinical perspective. Circulation [Internet]. 2016;134:1603–1612. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27576777%0Ahttp://circ.ahajournals.org/lookup/doi/10.1161/CIRCULATIONAHA.116.024823.
   PubMed Web of Science ®Google Scholar
• Motovska Z, Hlinomaz O, Kala P, et al. 1-Year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J Am Coll Cardiol. 2018;71:371–381.
   PubMed Web of Science ®Google Scholar
• Schüpke S, Neumann F-J, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381:1524–1534.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Aggarwal N, et al. Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 study. Circulation [Internet]. 2016 cited 2018 Jan 5;134:780–792. Available from: http://circ.ahajournals.org/lookup/doi/10.1161/CIRCULATIONAHA.116.023402.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv [Internet]. 2011 cited 2018 Feb 13;4:180–187. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21386092.
   PubMed Web of Science ®Google Scholar
• Gravel S, Chiasson J, Turgeon J, et al. Modulation of CYP 450 activities in patients with type 2 diabetes. Clin Pharmacol Ther [Internet]. 2019;106:1280–1289. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1496.
   PubMed Web of Science ®Google Scholar
• Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol [Internet]. 2008;52:1968–1977. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19055987.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Jakubowski JA, Ferreiro JL, et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol [Internet]. 2014;64:1005–1014. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25190236.
   PubMed Web of Science ®Google Scholar
• Conrotto F, Bertaina M, Raposeiras-Roubin S, et al. Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI. Eur Hear J Acute Cardiovasc Care. 2019;8:536–542.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Mehran R, Valgimigli M, et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol [Internet]. 2018;15:480–496. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29973709.
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la. Lancet [Internet]. 2018; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673618318580.
   Web of Science ®Google Scholar
• Chichareon P, Modolo R, Kogame N, et al. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. Atherosclerosis [Internet]. 2020;295:45–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32006758.
   PubMed Web of Science ®Google Scholar
• Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med [Internet]. 2019; Available from: http://www.ncbi.nlm.nih.gov/pubmed/31556978.
   Web of Science ®Google Scholar
• Angiolillo DJ, Baber U, Sartori S, et al. Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention. J Am Coll Cardiol [Internet]. 2020; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109720345307.
   Google Scholar
• Kim B-K, Hong S-J, Cho Y-H, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome. JAMA [Internet]. 2020;323:2407. Available from: https://jamanetwork.com/journals/jama/fullarticle/2767161.
   PubMed Web of Science ®Google Scholar
• Ticagrelor Monotherapy in Patients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial. 2019.
   Google Scholar
• Silvain J, Cayla G, Beygui F, et al. Blunting periprocedural myocardial necrosis: rationale and design of the randomized ALPHEUS study. Am Heart J. 2020;225:27–37.
   PubMed Web of Science ®Google Scholar
• Compare Efficacy and Safety of Clopidogrel vs Ticagrelor in Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention; TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI. 2014.
   Google Scholar
• Sahlén A, Varenhorst C, Lagerqvist B, et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J [Internet]. 2016 cited 2017 Aug 13;37:3335–3342. Available from: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehw284.
   PubMed Web of Science ®Google Scholar
• Timmis A, Rapsomaniki E, Chung SC, et al. Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations. BMJ. 2016;353:i3163.
   Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2014;64:e139–e228.
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2013;61:e78–e140.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J [Internet]. 2018 cited 2017 Oct 15;39:213–260. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28886622.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart association task force on clinical practice guidelines: an update. Circulation. 2016;134.
   Web of Science ®Google Scholar
• Capodanno D, Alfonso F, Levine GN, et al. ACC/AHA versus ESC Guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018 Dec 11;72(23 Pt A):2915-2931.
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J [Internet]. 2019;00:1–71. Available from: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehz425/5556137.
   Google Scholar
• Bonaca MP, Storey RF, Theroux P, et al. Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol. 2017;70:1368–1375.
   PubMed Web of Science ®Google Scholar
• Astra Zeneca. Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease. 2020.
   Google Scholar
• Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735.
   PubMed Web of Science ®Google Scholar
• Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet [Internet]. 2017 cited 2018 Mar 25;389:1025–1034. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28290994.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Angiolillo DJ. Tailoring duration of DAPT with risk scores. Lancet [Internet]. 2017 cited 2017 Jul 13;389:987–989. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28291000.
   PubMed Web of Science ®Google Scholar
• Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk. Eur Heart J. [Internet]. 2019; Available from: http://www.ncbi.nlm.nih.gov/pubmed/31116395.
   Google Scholar
• Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet [Internet]. 2018 cited 2019 Mar 15;391:205–218. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673617324583.
   PubMed Web of Science ®Google Scholar
• Buccheri S, Capodanno D, James S, et al. Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opin Drug Saf [Internet]. 2019;18:1171–1189. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31623473.
   PubMed Web of Science ®Google Scholar
• Kim C, Hong S-J, Shin D-H, et al. Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design. Am Heart J. 2019;212:45–52.
   PubMed Web of Science ®Google Scholar
• TICO: Ticagrelor Monotherapy Beneficial Post PCI in Patients With ACS.
   Google Scholar
• Capodanno D. Dual antiplatelet therapy after percutaneous coronary intervention: entering the final chapter? EuroIntervention. 2019;15:e475–e478.
   PubMed Web of Science ®Google Scholar
• Dangas G, Baber U, Sharma S, et al. Ticagrelor with aspirin or alone after complex PCI: the TWILIGHT-COMPLEX analysis. J Am Coll Cardiol. 2020 May 19;75(19):2414-2424.
   Google Scholar